{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:29:16Z","timestamp":1777922956708,"version":"3.51.4"},"reference-count":39,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>\n                    Methicillin-resistant\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    (MRSA) can be responsible for serious long-term infections. Sometimes monotherapy can be ineffective for the treatment of these infections; hence, it is hypothesized that combined drug treatment can be more potent in these cases. The aim of this study was to investigate the synergistic effect of vancomycin and eight other antibacterial agents to identify the best combination pattern in the management of MRSA. Ameri-Ziaee double synergism test (AZDAST), double-disc, checkerboard, and time-kill methods were used to assess the synergistic effect in 24 isolates of\n                    <jats:italic toggle=\"yes\">S. aureus<\/jats:italic>\n                    , including 22 MRSA and two methicillin-sensitive\n                    <jats:italic toggle=\"yes\">S. aureus<\/jats:italic>\n                    (MSSA). Furthermore, based on the results, handmade combined antibiotic discs were prepared to evaluate the results of the checkerboard and time-kill methods at the plate level. All the isolates were sensitive to vancomycin, linezolid, and daptomycin. Furthermore, penicillin had the highest resistance (100%) in all isolates. The synergistic activities were observed, when the vancomycin was combined with the imipenem, using three double-disc, checkerboard, and time-kill methods. The sub-minimum inhibitory concentration (MIC) amount of the combined discs could increase the diameter of the inhibition zone, confirming the results. The data obtained from this study suggested that vancomycin and imipenem together, even at sub-MIC, could be effective against MRSA and MSSA infections.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2019.0003","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T10:29:24Z","timestamp":1566210564000},"page":"218-226","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["<i>In Vitro<\/i>\n                    Synergistic Effect of Vancomycin and Some Antibacterial Agents Against Clinical Methicillin-Resistant and Sensitive\n                    <i>Staphylococcus aureus<\/i>\n                    Isolates"],"prefix":"10.1177","volume":"26","author":[{"given":"Hamideh","family":"Mohammadi-Berenjestanaki","sequence":"first","affiliation":[{"name":"Department of Microbiology, Golestan University of Medical Sciences, Gorgan, Iran."},{"name":"Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahid","family":"Khori","sequence":"additional","affiliation":[{"name":"Ischemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesamaddin","family":"Shirzad-Aski","sequence":"additional","affiliation":[{"name":"Infectious Diseases Research Center, Golestan University of Medical Sciences, Gorgan, Iran."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ezzat Allah","family":"Ghaemi","sequence":"additional","affiliation":[{"name":"Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,3,5]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1128\/AAC.01157-10","article-title":"The clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin resistant Staphylococcus aureus bloodstream infections","volume":"55","author":"de Kraker M.E.","year":"2011","unstructured":"de Kraker M.E., , Wolkewitz M., , Davey P.G, , Koller W., , Berger J., , Nagler J., , Icket C., , Kalenic S., , Horvatic J., , Seifert H., , Kaasch A.J, , Paniara O., , Argyropoulou A., , Bompola M., , Smyth E., , Skally M., , Raglio A., , Dumpis U., , Kelmere A.M, , Borg M., , Xuereb D., , Ghita M.C, , Noble M., , Kolman J., , Grabljevec S., , Turner D., , Lansbury L., , and Grundmann H.; BURDEN Study Group. 2011. The clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin resistant Staphylococcus aureus bloodstream infections. Antimicrob. Agents Chemother. 55:1598\u20131605.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2398-2402.2004"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/jac\/dkp494","article-title":"Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients","volume":"65","author":"Hill R.L.","year":"2010","unstructured":"Hill R.L., , Kearns A.M, , Nash J., , North S.E, , Pike R., , Newson T., , Woodford N., , Calver R., , and Livermore D.M.. 2010. Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J. Antimicrob. Chemother. 65:442\u2013445.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/sur.2011.068","article-title":"The changing face of Staphylococcus aureus: a continuing surgical challenge","volume":"12","author":"Barie P.S.","year":"2011","unstructured":"Fry. D.E., and Barie P.S.. 2011. The changing face of Staphylococcus aureus: a continuing surgical challenge. Surg. Infect. 12:191\u2013203.","journal-title":"Surg. Infect"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"e17936","DOI":"10.1371\/journal.pone.0017936","article-title":"A field guide to pandemic, epidemic and sporadic clones of methicillin-resistant Staphylococcus aureus","volume":"6","author":"Monecke S.","year":"2011","unstructured":"Monecke S., , Coombs G., , Shore A.C, , Coleman D.C, , Akpaka P., , Borg M., , Chow H., , Ip M., , Jatzwauk L., , and Jonas D.. 2011. A field guide to pandemic, epidemic and sporadic clones of methicillin-resistant Staphylococcus aureus. PLoS One, 6:e17936.","journal-title":"PLoS One"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-060614-034516"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00134-016-4572-4","article-title":"Treatment of severe MRSA infections: current practice and further development","volume":"43","author":"Paiva J.-A.","year":"2017","unstructured":"Paiva J.-A., , and Eggimann P.. 2017. Treatment of severe MRSA infections: current practice and further development. Intensive Care Med. 43:233\u2013236.","journal-title":"Intensive Care Med"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv368"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/2047-783X-15-12-507","article-title":"Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin?-Comparison of pharmacology and clinical efficacy","volume":"15","author":"Pletz M.W.","year":"2010","unstructured":"Pletz M.W., , Burkhardt O., , and Welte T.. 2010. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin?-Comparison of pharmacology and clinical efficacy. Eur. J. Med. Res. 15:507.","journal-title":"Eur. J. Med. Res"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1396906"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00134-006-0470-5","article-title":"Pharmacokinetic\/pharmacodynamic analysis of vancomycin in ICU patients","volume":"33","author":"Revilla N.","year":"2007","unstructured":"de Gatta, M.D.M.F., Revilla N., , Calvo M.V, , Dom\u00ednguez-Gil A., , and Navarro A.S.. 2007. Pharmacokinetic\/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med. 33:279\u2013285.","journal-title":"Intensive Care Med"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s10096-013-2023-5","article-title":"Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia","volume":"33","author":"Luo G.","year":"2014","unstructured":"Luo G., , Spellberg B., , Gebremariam T., , Lee H., , Xiong Y., , French S., , Bayer A., , and Ibrahim A.. 2014. Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia. Eur. J. Clin. Microbiol. Infect. Dis. 33:845\u2013851.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"e0117664","DOI":"10.1371\/journal.pone.0117664","article-title":"Combinations of \u03b2-lactam or aminoglycoside antibiotics with plectasin are synergistic against methicillin-sensitive and methicillin-resistant Staphylococcus aureus","volume":"10","author":"Hu Y.","year":"2015","unstructured":"Hu Y., , Liu A., , Vaudrey J., , Vaiciunaite B., , Moigboi C., , McTavish S.M, , Kearns A., , and Coates A.. 2015. Combinations of \u03b2-lactam or aminoglycoside antibiotics with plectasin are synergistic against methicillin-sensitive and methicillin-resistant Staphylococcus aureus. PLoS One, 10:e0117664.","journal-title":"PLoS One"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and \u03b2-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis J.S.","year":"2015","unstructured":"Davis J.S., , Sud A., , O'Sullivan M.V, , Robinson J.O, , Ferguson P.E, , Foo H., , van Hal S.J, , Ralph A.P, , Howden B.P, , and Binks P.M.. 2015. Combination of vancomycin and \u03b2-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin. Infect. Dis. 62:173\u2013180.","journal-title":"Clin. Infect. Dis"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1128\/AAC.49.1.45-51.2005","article-title":"In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus","volume":"49","author":"Jacqueline C.","year":"2005","unstructured":"Jacqueline C., , Navas D., , Batard E., , Miegeville A.-F, , Le Mabecque V., , Kergueris M.-F, , Bugnon D., , Potel G., , and Caillon J.. 2005. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:45\u201351.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01106-10"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/jac\/dks384","article-title":"Enhancement by novel anti-methicillin-resistant Staphylococcus aureus compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: in vitro and in vivo studies","volume":"68","author":"Hu Y.","year":"2012","unstructured":"Hu Y., , and Coates A.R.. 2012. Enhancement by novel anti-methicillin-resistant Staphylococcus aureus compound HT61 of the activity of neomycin, gentamicin, mupirocin and chlorhexidine: in vitro and in vivo studies. J. Antimicrob. Chemother. 68:374\u2013384.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.05.019"},{"key":"e_1_3_4_21_2","unstructured":"CLSI. 2016. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobila Susceptibilty Testing Clinical and Laboratory Standards Institute. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.8.2786-2790.2002"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mex.2016.01.002","article-title":"AZDAST the new horizon in antimicrobial synergism detection","volume":"3","author":"Ziaei-Darounkalaei N.","year":"2016","unstructured":"Ziaei-Darounkalaei N., , Ameri M., , Zahraei-Salehi T., , Ziaei-Darounkalaei O., , Mohajer-Tabrizi T., , and Bornaei L.. 2016. AZDAST the new horizon in antimicrobial synergism detection. MethodsX, 3:43\u201352.","journal-title":"MethodsX"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/2279-042X.99673","article-title":"Double-disk synergy test for detection of synergistic effect between antibiotics against nosocomial strains of Staphylococcus aureus","volume":"1","author":"Soltani R.","year":"2012","unstructured":"Soltani R., , Khalili H., , and Shafiee F.. 2012. Double-disk synergy test for detection of synergistic effect between antibiotics against nosocomial strains of Staphylococcus aureus. J. Res. Pharm. Pract. 1:21.","journal-title":"J. Res. Pharm. Pract"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","DOI":"10.1128\/9781555817435","volume-title":"Clinical Microbiology Procedures","author":"Garcia L.S.","year":"2010","unstructured":"Garcia L.S., , and Isenberg H.D.. 2010. Clinical Microbiology Procedures. Handbook.ASM Press, Washington, DC."},{"key":"e_1_3_4_26_2","first-page":"97","article-title":"Polymyxins and doripenem combination against KPC-producing Klebsiella pneumoniae","volume":"5","author":"Lee G.C.","year":"2013","unstructured":"Lee G.C., , and Burgess D.S.. 2013. Polymyxins and doripenem combination against KPC-producing Klebsiella pneumoniae. J. Clin. Med. Res. 5:97.","journal-title":"J. Clin. Med. Res"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"e0126479","DOI":"10.1371\/journal.pone.0126479","article-title":"Three dimensional checkerboard synergy analysis of colistin, meropenem, tigecycline against multidrug-resistant clinical Klebsiella pneumonia isolates","volume":"10","author":"Stein C.","year":"2015","unstructured":"Stein C., , Makarewicz O., , Bohnert J.A, , Pfeifer Y., , Kesselmeier M., , Hagel S., , and Pletz M.W.. 2015. Three dimensional checkerboard synergy analysis of colistin, meropenem, tigecycline against multidrug-resistant clinical Klebsiella pneumonia isolates. PLoS One, 10:e0126479.","journal-title":"PLoS One"},{"key":"e_1_3_4_28_2","first-page":"1","article-title":"Antimicrobial activity of Austroeupatorium inulaefolium (HBK) against intracellular and extracellular organisms","volume":"12","author":"Bua A.","year":"2017","unstructured":"Bua A., , Usai D., , Donadu M., , Delgado Ospina J., , Paparella A., , Chaves-Lopez C., , Serio A., , Rossi C., , Zanetti S., , and Molicotti P.. 2017. Antimicrobial activity of Austroeupatorium inulaefolium (HBK) against intracellular and extracellular organisms. Nat. Prod. Res. 12:1\u20133.","journal-title":"Nat. Prod. Res"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10156-005-0402-2","article-title":"Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan","volume":"11","author":"Kobayashi Y.","year":"2005","unstructured":"Kobayashi Y. 2005. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J. Infect. Chemother. 11:259\u2013261.","journal-title":"J. Infect. Chemother"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1128\/AAC.44.11.3055-3060.2000","article-title":"In vitro synergistic effects of double and triple combinations of \u03b2-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains","volume":"44","author":"Rochon-Edouard S.","year":"2000","unstructured":"Rochon-Edouard S., , Pestel-Caron M., , Lemeland J.-F, , and Caron F.. 2000. In vitro synergistic effects of double and triple combinations of \u03b2-lactams, vancomycin, and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. 44:3055\u20133060.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_31_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1590\/S0074-02762011000100007","article-title":"Evaluation of the synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp strains","volume":"106","author":"Silva L.V.D.","year":"2011","unstructured":"Silva L.V.D., , Ara\u00fajo M.T, , K.Santos R.N.D, , and Nunes A.P.F. 2011. Evaluation of the synergistic potential of vancomycin combined with other antimicrobial agents against methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus spp strains. Mem. Inst. Oswaldo Cruz. 106:44\u201350.","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"e_1_3_4_32_2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/jac\/44.4.455","article-title":"Combined effects of vancomycin and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo","volume":"44","author":"Totsuka K.","year":"1999","unstructured":"Totsuka K., , Shiseki M., , Kikuchi K., , and Matsui Y.. 1999. Combined effects of vancomycin and imipenem against methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo. J. Antimicrob. Chemother. 44:455\u2013460.","journal-title":"J. Antimicrob. Chemother"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.1.5-14.2003"},{"key":"e_1_3_4_34_2","article-title":"\u03b2-lactam combinations with vancomycin show synergistic activity against vancomycinsusceptible Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), and heterogeneous VISA. Antimicrob","volume":"62","author":"Tran K.N.","year":"2018","unstructured":"Tran K.N., , and Rybak M.J.. 2018. \u03b2-lactam combinations with vancomycin show synergistic activity against vancomycinsusceptible Staphylococcus aureus, vancomycin-intermediate S. aureus (VISA), and heterogeneous VISA. Antimicrob. Agents Chemother. 62: e00157-18.","journal-title":"Agents Chemother"},{"key":"e_1_3_4_35_2","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1128\/AAC.02354-12","article-title":"Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA","volume":"57","author":"Werth B.","year":"2013","unstructured":"Werth B., , Vidaillac C., , Murray K., , Newton K., , Sakoulas G., , Nonejuie P., , Pogliano J., , and Rybak M.. 2013. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob. Agents Chemother. 57:2376\u20132379.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1128\/AAC.01888-13","article-title":"Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus isolates and vancomycin-intermediate Staphylococcus aureus isolates in vitro","volume":"58","author":"Dilworth T.J.","year":"2014","unstructured":"Dilworth T.J., , Sliwinski J., , Ryan K., , Dodd M., , and Mercier R.-C.. 2014. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus isolates and vancomycin-intermediate Staphylococcus aureus isolates in vitro. Antimicrob. Agents Chemother. 58:1028\u20131033.","journal-title":"Antimicrob. Agents Chemother"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-014-0023-0"},{"key":"e_1_3_4_38_2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1128\/JCM.01779-15","article-title":"Synergy of \u03b2-lactams with vancomycin against methicillin-resistant staphylococcus aureus: correlation of disk diffusion and checkerboard methods","volume":"54","author":"Sy C.L.","year":"2016","unstructured":"Sy C.L., , Huang T.-S, , Chen C.S, , Chen Y.-S, , Tsai H.-C, , Wann S.-R, , Wu K.-S, , Chen J.-K, , Lee S.S.-J, , and Liu Y.-C.. 2016. Synergy of \u03b2-lactams with vancomycin against methicillin-resistant staphylococcus aureus: correlation of disk diffusion and checkerboard methods. J. Clin. Microbiol. 54:565\u2013568.","journal-title":"J. Clin. Microbiol"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"O255","DOI":"10.1111\/1469-0691.12373","article-title":"Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories","volume":"20","author":"Matuschek E.","year":"2014","unstructured":"Matuschek E., , Brown D.F.J, , and Kahlmeter G.. 2014. Development of the EUCAST disk diffusion antimicrobial susceptibility testing method and its implementation in routine microbiology laboratories. Clin. Microbiol. Infect. 20:O255\u2013O266.","journal-title":"Clin. Microbiol. Infect"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-7-111"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2019.0003","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:34:51Z","timestamp":1777667691000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2019.0003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1089\/mdr.2019.0003"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2019.0003","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}